Effect of glycosidation of isoflavones on their bioavailability and pharmacokinetics in aged male rats

Molecular Nutrition and Food Research

Volumn 53, Issue SUPPL. 1, 2009, Pages

  Sepehr, Estatira ^a,b   Cooke, Gerard M ^a,b   Robertson, Patrick ^a   Gilani, G Sarwar ^a  

^a Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bioavailability; Isoflavones; LC MS; Plasma pharmacokinetics

Indexed keywords

DAIDZEIN; EQUOL; GENISTEIN; GLUCOSIDE; GLYCITEIN; ISOFLAVONE DERIVATIVE; PHYTOESTROGEN;

AGING; ANIMAL; ARTICLE; BIOAVAILABILITY; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DIET; FISCHER 344 RAT; GLYCOSYLATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; RAT; SOYBEAN;

AGING; ANIMALS; BIOLOGICAL AVAILABILITY; DIET; GENISTEIN; GLUCOSIDES; GLYCOSYLATION; INJECTIONS, INTRAVENOUS; ISOFLAVONES; MALE; PHYTOESTROGENS; RATS; RATS, INBRED F344; SOYBEANS;

ANIMALIA; RATTUS;

EID: 67649949381     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200800170     Document Type: Article

References (75)

1. Bandele, O. J., Osheroff, N., Bioflavonoids as poisons of human topoisomerase IIα and IIβ, Biochemistry 2007, 46, 6097-6108.
2. Adlercreutz, H., Mazur, W., Phytoestrogens and Western disease, Ann. Med. 1997, 29, 95-120.
3. Setchell, K. D., Brown, N. M., Lydeking-Olsen, E., The clinical importance of the metabolite equol-a clue to the effective-ness of soy and its isoflavones, J. Nutr. 2002, 132, 3577-3584.
4. Cassidy, A., Brown, J. E., Hawdon, A., Faughnan, M. S., et al., Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods, J. Nutr. 2006, 136, 45-51.
5. King, R. A., Broadbent, J. L., Head, R. J., Absorption and excretion of the soy isoflavone genistein in rats, J. Nutr. 1996, 126, 176-182.
6. Piskula, M. K., Yamakoshi, J., Iwai, Y., Daidzein and genistein but not their glucosides are absorbed from the rat stomach, FEBS Lett. 1999, 447, 287-291.
7. Piskula, M. K., Soy isoflavone conjugation differs in fed and food deprived rats, J. Nutr. 2000, 130, 1766-1771.
8. Xu, X., Wang, H. J., Murphy, P. A., Cook, L., Hendrich, S., Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women. J. Nutr. 1994, 124, 825-832.
9. Franke, A. A., Custer, L. J., Daidzein and genistein concentrations in human milk after soy consumption. Clin. Chem. 1996, 42, 955-964.
10. Izumi, T., Piskula, M. K., Osawa, S., Obata, A., et al., Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans, J. Nutr. 2000, 130, 1695-1699.
11. Zubik, L., Meydani, M., Bioavailability of soybean isoflavones from aglycone and glucoside form in American women. Am. J. Clin. Nutr. 2003, 77, 1459-1465.
12. de-Pascual-Teresa, S., Hallund, J., Talbot, D., Schroot, J., et al., Absorption of isoflavones in humans: Effects of food matrix and processing. J. Nutr. Biochem. 2006, 17, 257-264.
13. Yu, H., Harris, R. E., Gao, Y. T., Gao, R., Wynder, E. L., Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States, Int. J. Epidemiol. 1991, 20, 76-81.
14. Adlercreutz, H., Western diet and Western diseases: Some hormonal and biochemical mechanisms and associations, Scand. J. Clin. Lab. Invest. Suppl. 1990, 201, 3-23.
15. Adlercreutz, H., Hämäläinen, E., Gorbach, S., Goldin, B., Dietary phyto oestrogens and the menopause in Japan, Lancet 1992, 339, 1233.
16. Morton, M., Matos-Ferreira, A., Abranches-Monteiro, L., Correia, R. et al., Measurements and metabolism of isoflavonoids and lignans in the human male, Cancer Lett. 1997, 114, 145-151.
17. Messina, M., Kucuk, O., Lampe, J. W., An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels, J. AOAC Int. 2006, 89, 1121-1134.
18. Setchell, K. D. R., Brown, N. M., Desai, P., Zimmer-Nechemias, L. et al., Bioavailability of pure isoflavones in healthy humans and analysis of commercial Soy isoflavone supplements, J. Nutr. 2001, 131, 1362S-1375S.
19. Messina, M., Brief historical overviewof isoflavone research, in: Gilani, G. S., Anderson J (Eds.), Phytoestrogens and Health, AOAC Press, Champaign, IL, USA 2002.
20. Gilani, G. S., Betz, J. M., Role of accurate methodology in demonstrating the safety and efficacy of phytoestrogens, J. AOAC Int. 2006, 89, 1120.
21. United Nations demographic year book 2004, New York, USA.
22. McLean, A. J., Le Couteur, D. G., Aging biology and geriatric clinical Pharmacology, Am. Soc. Pharm. Exp. Ther. 2004, 56, 163-184.
23. Mutschler, E., Derendorf, H., Drug Actions Basic Principles and Therapeutic Aspects, Medpharm Scientific Publishers, CRC Press, Stuttgart 1995, 799-801.
24. Del Piano, M., Ballare, M., Montino, F., Orsello, M., et al., Clinical experience with probiotics in the elderly on total enteral nutrition, J. Clin. Gastroenterol. 2004, 38, S111-S114.
25. Crooks, J., O'Malley, K., Stevenson, I. H., Pharmacokinetics in the elderly, Clin. Pharmacokinet. 1976, 1, 280-296.
26. Setchell, K. D. R., Zimmer-Nechimias, L., Cai, J., Heubi, J. E., Exposure of infants to phytoestrogens from soybased infant formula, Lancet 1997, 350, 23-27.
27. Gilani, G. S., Sepehr, E., Protein digestibility and quality in products containing antinutritional factors are adversely affected by old age in rats, J. Nutr. 2003, 133, 220-225.
28. Wang, L., Banu, J., Mcmahan, C. A., Kalu, D. N., Male rodent model of age-related bone loss in men, Bone 2001, 29, 141-148.
29. Pacher, P., Mabley, J. G., Liaudet, L., Evgenov, O. V., et al., Left ventricular pressure volume relationship in a rat model of advanced aging associated heart failure, Am. J. Phys. Hearth Circ. Phys. 2004, 287, H2132-H2137.
30. Sepehr, E., Cooke, G. M., Robertson, P., Gilani, S. G., Bioavailability of soy isoflavones in rats, Part I: Application of accurate methodology for studying the effects of gender and source of isoflavones, Mol. Nutr. Food Res. 2007, 51, 799-812.
31. Chang, H. C., Churchwell, M. I., Delclos, K. B., Newbold, R. R., Doerge, D. R., Mass spectrometric determination of Genistein tissue distribution in diet-exposed Sprague-Dawley rats, J. Nutr. 2000, 130, 1963-1970.
32. Faughnan, M. S., Hawdon, A., Ah-Singh, E., Brown, J., et al., Urinary isoflavone kinetics: The effect of age, gender, food matrix and chemical composition, Br. J. Nutr. 2004, 91, 567-574.
33. Setchell, K. D. R., Brown, N. M., Desai, P. B., Zimmer-Nechimias, L. et al., Bioavailability, disposition and dose response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes, J. Nutr. 2003, 133, 1027-1035.
34. Sepehr, E., Robertson, P., Gilani, S. G., Cooke, G. M., et al., An accurate and reproducible method for the quantitative analysis of isoflavones and their metabolites in rat plasma using liquid chromatography/mass spectrometry combined with photodiode array detection, J. AOAC Int. 2006, 89, 1157-1168.
35. Wang, H.-J., Murphy, P. A., Isoflavone content in commercial soybean foods, J. Agric. Food Chem. 1994, 42, 1666-1673.
36. Irvine, C. H. G., Fitzpatrick, M. G., Alexander, S. L., Phytoestrogens in soy-based infant foods: Concentrations, daily intake, and possible biological effects, Proc. Soc. Exp. Biol. Med. 1998, 217, 247-253.
37. Zung, A., Reifen, R., Kerem, Z., Zadik, Z., Phytoestrogens: The pediatric perspective, J. Paediatric Gastroenterol. Nutr. 2001, 33, 112-118.
38. Reeves, P. G., Nielsen, F. H., Fahey, G., AIN-93 purified diets for laboratory rodents: Final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet, J. Nutr. 1993, 123, 1939.
39. Coldham, N. G., Zhang, A., Key, P., Sauer, M. J., Absolute bioavailability of [14C] genistein in the rat; plasma pharmacokinetics of parent compound, genistein glucuronide and total radioactivity, Eur. J. Drug Metab. Pharmacokinet. 2002, 27, 249-258.
40. Coldham, N. G., Sauer, M. J., Pharmacokinetics of [14C] genistein in the rat; gender-related differences, potential mechanisms of biological action, and implications for human health, Toxicol. Appl. Pharmacol. 2000, 164, 206-215.
41. Janning, P., Schuhmacher, U. S., Upmeier, A., Diel, P., et al., Toxicokinetics of the phytoestrogens daidzein in female DA/Han rats, Arch. Toxicol. 2000, 74, 421-430.
42. Moon, Y. J., Sagawa, K., Frederick, K., Zhang, S., et al., Pharmacokinetics and bioavailability of isoflavones Biochanin A in rats, AAPS J. 2006, 8, E433-E442.
43. Busby, M. G., Jeffcoat, A. R., Bloedon, L. T., Koch, M. A., et al., Clinical characteristics and pharmacokinetics of purified soy isoflavones: Single-dose administration to healthy men, Am. J. Clin. Nutr. 2002, 75, 126-136.
44. Bloedon, L. T., Jeffcoat, A. R., Lopaczynski, W., Schell, M. J., et al., Safety and pharmacokinetics of purified soy isoflavones: Single-dose administration to postmenopausal women, Am. J. Clin. Nutr. 2002, 76, 1126-1137.
45. Kano, M., Takayanagi, T., Harada, K., Sawada, S., Ishikawa, F., Bioavailability of isoflavones after ingestion of soy beverages in healthy adults, J. Nutr. 2006, 136, 2291-2296.
46. Joshi, J. V., Vaidya, R. A., Pandey, S. N., Agashe, S., et al., Plasma levels of genistein following a single dose of soy extract capsule in Indian women, Indian J. Med. Res. 2007, 125, 534-541.
47. Adlercreutz, H., Fotsis, T., Watanabe, S., Lampe, I., et al., Determination of lignans and isoflavonoids in plasma by isotope dilution gas chromatography-mass spectrometry, Cancer Detect. Prev. 1994, 18, 259-271.
48. Setchell, K. D. R., Zimmer-Nechimias, L., Cai, J., Heubi, J. E., Exposure of infants to phytoestrogens from soybased infant formula, Lancet 1997, 350, 23-27.
49. Aghazadeh-Habashi, A., Ibrahim, A., Carran, J., Anastassiades, T., Jamali, F., Single dose pharmacokinetics and bioa-vailability of butyryl glucosamine in the rat, J. Pharm. Pharm. Sci. 2006, 9, 359-364.
50. Brown, J. P., Hydrolysis of glycosides and esters, in: Rowland, I. R. (Ed.), Role of the Gut Flora in Toxicity and Cancer, Academic Press, San Diego, CA 1988, pp. 109-144.
51. Hendrich, S., Bioavailability of isoflavones, J. Chromatogr. B 2002, 777, 203-210.
52. Lee, S. H., Kim, Y. H., Yu, H. J., Cho, N. S., et al., Enhanced bioavailability of soy isoflavones by complexation with β-Cyclodextrin in rats, Biosci. Biotechnol. Biochem. 2007, 71, 2927-2933.
53. Song, T. T., Hendrich, S., Murphy, P. A., Estrogenic activity of glycitein, a soy isoflavone, J. Agric. Food Chem. 2002, 50, 2470.
54. Simons, A. I., Renouf, M., Hendrich, S., Murphy, P. A., Metabolism of glycitein (7, 49-Dihydroxy -6 methoxy-isofla-vone) by human gut microflora, J. Agric. Food Chem. 2005, 53, 8519-8525.
55. Jia, X., Chen, J., Lin, H., Hu, M., Disposition of flavonoids via enteric recycling: Enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates, J. Pharmacol. Exp. Ther. 2004, 310, 1103-1113.
56. Richelle, M., Pridmore-Merten, S., Bodenstab, S., Enslen, M., Offord, E. A., Hydrolysis of isoflavone glycosides to aglycones by beta-glycosides does not alter plasma and urine isoflavone pharmacokinetics in post menopausal women. Third international Symposium on the role of soy in preventing and treating chronic disease, J. Nutr. 2002, 132, 2587-2592.
57. Marchbanks, C. R., Mikolich, D. J., Mayer, K. H., Zinner, S. H., Dudley, M. N., Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections, Antimicrob. Agents Chemother. 1990, 34, 1966-1972.
58. Shelnutt, S. R., Cimino, C. O., Wiggins, P. A., Ronis, M. J., et al., Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage, Am. J. Clin. Nutr. 2002, 76, 588-594.
59. Rowland, I. R., Wiseman, H., Sanders, T. A., Adlercreutz, H., Bowey, E. A., Interindividual variation in metabolism of soy isoflavones and lignans: Influence of habitual diet on equol production by the gut microflora, Nutr. Cancer 2000, 36, 27-2.
60. Doerge, D. R., Chang, H. C., Holder, C. L., Churchwell, M. I., Enzymatic conjugation of soy isoflavones, genistein and daidzein, and analysis in human blood using liquid chromatography and mass spectrometry, Drug Metab. Dispos. 2002, 28, 298-307.
61. Holder, C. L., Churchwell, M. I., Doerge, D. R., Quantification of soy isoflavones, genistein and daidzein, and conjugates in rat blood using LC/ES-MS, J. Agric. Food Chem. 1999, 47, 3764-3770.
62. Liu, Y., Hu, M., Absorption and metabolism of flavonoids in the Caco-2 cell culture model and a perfused rat intestinal model, Drug Metab. Dispos. 2002, 30, 370-377.
63. T'ien-Li, Y., Hsiu-Yuan, C., The metabolic fate of daidzein, Sci. Sin. 1977, 20, 513-521.
64. Watanabe, S., Yamaguchi, M., Sobue, T., Takahashi, T., et al., Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder, J. Nutr. 1998, 128, 1710-1715.
65. Setchell, K. D. R., Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones, Am. J. Clin. Nutr. 1998, 68, 1333S-1346S.
66. Axelaon, M., Setchell, K. D., The excretion of lignans in rats-evidence for an intestinal bacterial source for this new group of compounds, FEBS Lett. 1981, 123, 337-342.
67. Setchell, K. D., Clerici, C., Lephart, E. D., Cole, S. J., et al., Heubi JE.S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora, Am. J. Clin. Nutr. 2005, 81, 1072-1079.
68. Vatanparast, H., Chilibeck, P. D., Does the effect of soy phytoestrogens on bone in postmenopausal women depend on the equol producing phynotype? Nutr. Rev. 2006, 65, 294-299.
69. Clavel, T., Fallani, M., Lepage, P., Levenez, F., et al., Isoflavones and functional foods alter the dominant intestinal microbiota in postmenopausal women, J. Nutr. 2005, 135, 2786-2792.
70. Ueno, T., Uchiyama, S., Identification of the specific intestinal bacteria capable of metabolising soy isoflavone to equol, Ann. Nutr. Metab. 2001, 45, 114.
71. Gorbach, S. L., Nahas, L., Lerner, P. I., Weinstein, L., Studies of intestinal microflora. I. Effects of diet, age, and periodic sampling on numbers of fecal microorganisms in man, Gastroenterology 1967, 53, 845-855.
72. Franks, A. H., Harmsen, H. J., Raangs, G. C., Jansen, G. J., et al., Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes, Appl. Environ. Microbiol. 1998, 64, 3336-3345.
73. Finegold, S. M., Sutter, V. L., Mathisen, G. E., Normal indigenous intestinal flora, in: Hentges, D. J. (Ed.), Human Intestinalmicroflora in Health and Disease, Academic Press, New York 1983, pp. 3-31.
74. Benno, Y., Mitsuoka, T., Kanazawa, K., Human faecal flora in health and colon cancer, Acta Chir. Scand. 1991, 62, 15-23.
75. Hopkins, M. J., Macfarlane, G. T., Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection, J. Med. Microbiol. 2002, 51, 448-454.